Literature DB >> 31498754

Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy.

David J VanderWeele1, Emmanuel S Antonarakis2, Michael A Carducci2, Robert Dreicer3, Karim Fizazi4, Silke Gillessen5, Celeste S Higano6, Alicia K Morgans1, Daniel P Petrylak7, Christopher J Sweeney8, Maha Hussain1.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31498754     DOI： 10.1200/JCO.19.01595

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

Review 1.  Epigenetics in prostate cancer: clinical implications.

Authors:  Vincenza Conteduca; Judy Hess; Yasutaka Yamada; Sheng-Yu Ku; Himisha Beltran
Journal:  Transl Androl Urol       Date:  2021-07

2.  Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer.

Authors:  Philip W Kantoff; Wassim Abida; Konrad H Stopsack; Subhiksha Nandakumar; Andreas G Wibmer; Samuel Haywood; Emily S Weg; Ethan S Barnett; Chloe J Kim; Emily A Carbone; Samantha E Vasselman; Bastien Nguyen; Melanie A Hullings; Howard I Scher; Michael J Morris; David B Solit; Nikolaus Schultz
Journal:  Clin Cancer Res       Date:  2020-03-27       Impact factor: 12.531

Review 3.  WHICH PATIENTS WILL BENEFIT MOST FROM DOCETAXEL ADDITION TO ANDROGEN DEPRIVATION THERAPY (ADT) IN METASTATIC CASTRATE-SENSITIVE PROSTATE CANCER (MCSPC)?

Authors:  Marija Gamulin; Marko Bebek; Milena Gnjidic
Journal:  Acta Clin Croat       Date:  2019-11       Impact factor: 0.780

4.  Looking for a Simplified Diagnostic Model to Identify Potentially Lethal Cases of Prostate Cancer at Initial Diagnosis: An ImGO Pilot Study.

Authors:  Serena Macrini; Simona Francesconi; Cecilia Caprera; Daniela Lancia; Matteo Corsi; Marco Gunnellini; Andrea Rocchi; Anjuta Pireddu; Fiovo Marziani; Claudia Mosillo; Maria Letizia Calandrella; Claudia Caserta; Diana Giannarelli; Annalisa Guida; Stefano Ascani; Sergio Bracarda
Journal:  Cancers (Basel)       Date:  2022-03-17       Impact factor: 6.639

5.  Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer.

Authors:  Miguel Gonzalez Velez; Heidi E Kosiorek; Jan B Egan; Andrea L McNatty; Irbaz B Riaz; Steven R Hwang; Glenn A Stewart; Thai H Ho; Cassandra N Moore; Parminder Singh; Renee K Sharpsten; Brian A Costello; Alan H Bryce
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-07-22       Impact factor: 5.455
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.